Sanofi Finalizes Blueprint Medicines Deal Adding Ayvakit and Robust SM Pipeline

(IN BRIEF) Sanofi has completed its purchase of Blueprint Medicines, acquiring the approved systemic mastocytosis therapy Ayvakit/Ayvakyt (avapritinib), along with two pipeline candidates: elenestinib (a KIT D816V inhibitor in Phase 2/3 HARBOR, NCT04910685) and BLU‑808 (a wild‑type KIT inhibitor). The $129.00‑per‑share tender offer, including a contingent right for up to $6.00 more upon milestone achievement, closed on 17 July 2025. Blueprint becomes an indirect, wholly‑owned Sanofi subsidiary and will delist from NASDAQ on 18 July. Funded via cash and commercial paper, the acquisition is immediately margin‑accretive and will boost operating income and EPS after 2026, with no significant impact on Sanofi’s 2025 financial outlook.

(PRESS RELEASE) PARIS, 18-Jul-2025 — /EuropaWire/ — Sanofi has finalized its acquisition of Blueprint Medicines Corporation, integrating a marketed therapy, a robust R&D pipeline, and Blueprint’s specialized expertise in systemic mastocytosis (SM) and other KIT‑driven disorders into its immunology franchise. This transaction strengthens Sanofi’s footprint among allergists, dermatologists, and immunologists, further bolstering its expanding immunology portfolio.

Key assets acquired include Ayvakit (avapritinib), the only approved treatment for both advanced and indolent systemic mastocytosis in the US and EU, and a growing indication in unresectable or metastatic GIST with PDGFRA exon 18 mutations. Blueprint’s late‑stage candidate elenestinib—a potent, selective KIT D816V inhibitor with limited CNS penetration—is now advancing in the Phase 2/3 HARBOR study (NCT04910685) for indolent and smoldering SM. Additionally, Sanofi gains BLU‑808, an investigational oral wild‑type KIT inhibitor targeting mast cell–mediated inflammatory diseases.

The tender offer for all outstanding Blueprint shares, at $129.00 per share plus one contingent right for up to $6.00 per share upon achievement of defined milestones, expired on 17 July 2025 at 17:00 EDST. With all conditions met, Sanofi accepted and is promptly paying for all validly tendered shares. Remaining shares were converted into the same cash and contingent‑right package. Blueprint will cease trading on the NASDAQ Global Select Market as of 18 July 2025.

Sanofi funded the deal with cash on hand and short‑term commercial paper; the acquisition is immediately accretive to gross margin and, post‑2026, to operating income and EPS, without materially altering 2025 guidance.

About Ayvakit
Ayvakit (avapritinib) is the first and only medicine approved by the US Food and Drug Administration (FDA) to treat the root cause of SM. It was FDA approved for the treatment of advanced SM in June 2021 and indolent SM in May 2023. It now is indicated in adults with ISM, adults with advanced SM, including aggressive SM (ASM), SM with an associated hematological neoplasm (SM-AHN) and mast cell leukemia (MCL), and adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. The medicine is approved in the EU as Ayvakyt for the treatment of adults with ISM with moderate to severe symptoms inadequately controlled on symptomatic treatment, adults with ASM, SM-AHN or MCL, after at least one systemic therapy, and adults with unresectable or metastatic GIST harboring the PDGFRA D842V mutation. Globally, the medicine is approved for one or more indications in 16 countries, including China where it is marketed by CStone Pharmaceuticals, paying tiered percentage royalties on sales.

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Sanofi forward-looking statements
Forward-looking statements are statements that are not historical facts. These statements may include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product, and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “will be”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful and other risks associated with executing business combination transactions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the acquisition will not be realized, risks related to future opportunities and plans for the combined company, including uncertainty of the expected financial performance and results of the combined company following completion of the proposed acquisition, disruption from the proposed acquisition making it more difficult to conduct business as usual or to maintain relationships with customers, employees, manufacturers, suppliers or patient groups, and the possibility that, if the combined company does not achieve the perceived benefits of the proposed acquisition as rapidly or to the extent anticipated by financial analysts or investors, the market price of Sanofi’s shares could decline, as well as other risks related to Sanofi’s business, including the ability to grow sales and revenues from existing products and to develop, commercialize or market new products, competition, including potential generic competition, the uncertainties inherent in research and development, including future clinical data and analysis, regulatory obligations and oversight by regulatory authorities, such as the FDA or the EMA, including decisions of such authorities regarding whether and when to approve any drug, device or biological application that may be filed for any product candidates as well as decisions regarding labelling and other matters that could affect the availability or commercial potential of any product candidates, the absence of a guarantee that any product candidates, if approved, will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the US Securities and Exchange Commission (the “SEC”) and the Autorité des marchés financiers made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Sanofi Finalizes Blueprint Medicines Deal Adding Ayvakit and Robust SM Pipeline

SEARCH 30,000+ EUROPEAN PRESS RELEASES

About EuropaWire

PRs by Dates

Industries & Countries

Archived PRs

Recent PRs

POPULAR TAGS

Links